Abiopharma

Sesen Bio Inc (merger with a company Carisma Therapeutics Inc (NASDAQ:CARM)) (SESN) Announces Clinical Trial Update Sesen Bio Inc (merger with a company Carisma Therapeutics Inc (NASDAQ:CARM)) (SESN) provided an update on its clinical development programs. Clinical Development Highlights:

• Collaboration: CFR
  • anticipated in such forward-looking statements as a result of these risks and uncertainties, including the risk that the Company may not be successful in identifying one or more strategic alternatives or ultimately pursuing a strategic alternative that delivers the anticipated benefits or enhances shareholder value, among other risks and uncertainties. A further description of the risks and uncertainties relating to the business of the Company is contained in the Company’s most recent annual report on Form 10-K and the Company’s quarterly reports on Form 10-Q, as well as any amendments thereto reflected in subsequent filings with the Securities and Exchange Commission. The Company undertakes no duty or obligation to update any forward-looking statements contained in this report as a result of new information, future events or changes in its expectations.SIGNATUREPursuant to the requirements of the Securities Exchange Act of 1934